Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan

Fig. 1

Suppression of SLE by irinotecan in MRL/lpr mice. Beginning at 8 weeks of age, MRL/lpr mice (n = 10 per group) were treated with saline, or 25 mg/kg or 1 mg/kg irinotecan. Treatment was performed three times a week and repeated every fourth week. a Frequency of proteinuria measured as grade 4+ at two consecutive weeks. b Skin score semiquantitatively assessed at the snout, ears, and dorsal region. Percent survival, showing animals sacrificed c due to lupus nephritis and excluding mice sacrificed due to skin lesions (n = 8 for saline, n = 10 for 25 mg/kg irinotecan, and n = 7 for 1 mg/kg irinotecan) or d including both lupus nephritis and skin lesions as sacrifice criteria (n = 10 for each group). Values represent the mean ± SEM. *P < 0.05, **P < 0.01, versus saline-treated MRL/lpr mice by two-way analysis of variance corrected by Bonferroni’s multiple comparisons test (a and b) or Mantel-Cox log rank test (c and d)

Back to article page